Last reviewed · How we verify
Fluarix-AS01E
At a glance
| Generic name | Fluarix-AS01E |
|---|---|
| Also known as | Fluarix vaccine adjuvanted with AS01E |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine (PHASE2)
- A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine
- Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluarix-AS01E CI brief — competitive landscape report
- Fluarix-AS01E updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI